Wednesday, March 23, 2022 12:52:59 AM
hyperopia: I appreciate the context you have given regarding BATON. I am searching for the reason why this "new" manufacturing method was patented now without any trials ongoing. I have come up with 3 possible reasons:
1) Other organizations are close to patenting something close, and they want to own the IP.
2) Part of the conditions for potentially selling NWBO dictate securing patents surrounding and including the new processes that can be used in conjunction with DCVax.
3) This is signaling intent to pursue a broader treatment approach ahead for the solid cancer space.
My main concern with having a patent w/o associated trials is of course by the time a future trial is complete there will not be much patent life left unless improvements can be made to extend the protection.
Your comment that they could just license the technology to generate cash could be the reason as well.
I am obviously missing a concept here since this move doesn't make sense to me regarding the path outlined for commercializing DCVax-L.
Peace.
1) Other organizations are close to patenting something close, and they want to own the IP.
2) Part of the conditions for potentially selling NWBO dictate securing patents surrounding and including the new processes that can be used in conjunction with DCVax.
3) This is signaling intent to pursue a broader treatment approach ahead for the solid cancer space.
My main concern with having a patent w/o associated trials is of course by the time a future trial is complete there will not be much patent life left unless improvements can be made to extend the protection.
Your comment that they could just license the technology to generate cash could be the reason as well.
I am obviously missing a concept here since this move doesn't make sense to me regarding the path outlined for commercializing DCVax-L.
Peace.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
